VRX Stock: Valeant Pharmaceuticals Intl Inc Is Oversold and Underloved

Advertisement

Valeant Pharmaceuticals Intl Inc (VRX) has certainly been on a wild ride of late, following on the heels of a negative Wells Fargo analyst report, further negative comments from famed short seller Jim Chanos and a report from the Wall Street Journal Monday afternoon hinting that Valeant was likely to restate earnings.

VRX Stock: Valeant Is Oversold and UnderlovedValeant stock, however, rebounded sharply yesterday after the alleged restatement failed to materialize.

This type of price action is indicative of a bottom in the VRX stock price, with the after-hours stock chart showing a wash-out in Valeant.

The short-term lows may be in for Valeant.

VRX888
Click to Enlarge
The 5-minute chart shows how Valeant stock plummeted nearly 10% to a low of $68 after hours Monday following the release of the Wall Street Journal report, only to rebound and trade higher. This type of reversal pattern is normally a bullish sign, with the weak longs capitulating and the shorts covering aggressively.

It also reinforces the risk of trading after hours with less-than-complete information.

On a longer-term technical basis, Valeant stock looks attractive on the chart as well. VRX traded down to critical support at the $72.43 level on Monday before reversing and closing well off the lows at $75.92. Yesterday saw Valeant shares add to the gains on an overall bad market day, closing higher by more than 4% at $79.27.

VRX Stock Bullish Put Spread

VRX88
Click to Enlarge
30-day implied volatility (IV) remains elevated at 96.84 (a reliable contrary bullish indicator), while nine-day RSI bounced off the oversold level of 30. With IV at lofty levels, option selling strategies make sense, so I am positioning by selling a guardedly bullish option put spread.

Specifically, I am selling the March $65 puts and buying the March $62 puts for a 55-cents net credit. These are regular monthly options that expire March 18.

The $65 strike is 18% below the $79.27 Tuesday closing price of VRX stock, providing ample downside cushion. The $65 level also equates to the price target from the bearish Wells Fargo analyst report.

The maximum gain on the trade is $55 per spread, with the maximum risk being $245 per spread. Return on risk is 22.4%.

I would look to close out the position on a meaningful break below the $68 level, while looking to let the position expire and keep the initial $55 credit if Valeant stock remains well-behaved.

As of this writing, Tim Biggam did not hold a position in any of the aforementioned securities. Anyone interested in finding out more about option-based strategies or for a free trial of the Delta Desk Research Report can email Tim at tbiggam@deltaderivatives.com.

More From InvestorPlace

Tim spent 13 years as Chief Options Strategist at Man Securities in Chicago, four years as Lead Options Strategist at ThinkorSwim and three years as a Market Maker for First Options in Chicago. Tim makes weekly appearances on Bloomberg TV  “Options Insight”, Business First AM “Trader Talk”, TD Ameritade Network “Morning Trade Live” and CBOE-TV “Vol 411” to discuss everything from volatility and option related.


Article printed from InvestorPlace Media, https://investorplace.com/2016/02/vrx-stock-valeant-options/.

©2024 InvestorPlace Media, LLC